Green Griffith focuses exclusively on IP issues involving pharmaceuticals, biologics, chemistry and medical devices—specializing in litigation.  Our attorneys share decades of litigation experience assisting both brand and generic companies navigate IP and related FDA issues, including the Hatch-Waxman Act.  As stated in AIM Patent 1000: “Green, Griffith is a uniquely talented and experienced intellectual property firm that has been making serious waves in the biopharmaceutical market.  As for the Green, Griffith modus operandi, they are tirelessly committed to helping their clients succeed; collaborating with their clients as strategic partners–albeit partners who happen to be excellent at litigation … their success rate speaks for itself.”

Acknowledged leaders in our field, we partner with our clients to provide strategic due diligence, formulation, portfolio and litigation counseling concerning IP and related FDA issues affecting 505(b)(1), 505(b)(2) and ANDA applications, as well as biologics (BPCIA).  Pre-litigation, we provide strategies and opinions directed toward attaining each client’s goals, whether this involves API and excipient selection, trade dress, formulation attributes, labeling or portfolio development.  Our trial attorneys—who have hard science backgrounds in chemistry, biology and/or biotechnology—then work with each client to execute the desired strategy—whether this involves litigation in the federal courts or IPR practice before the PTAB.  Visit: www.greengriffith.com